TNFSF13B rs9514828 C>T Polymorphism is Associated with Incidence of Atherosclerosis and Therapeutic Outcomes in Patients with Systemic Lupus Erythematosus

References

• Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int. 2015;112(25):423–432. doi:10.3238/arztebl.2015.0423
   PubMed Web of Science ®Google Scholar
• Thong B, Olsen NJ. Systemic lupus erythematosus diagnosis and management. Rheumatol. 2017;56:i3–i13. doi:10.1093/rheumatology/kew401
   PubMed Web of Science ®Google Scholar
• Shin J, Lee KH, Park S, et al. Systemic lupus erythematosus and lung involvement: a comprehensive review. J Clin Med. 2022;11(22):1–23. doi:10.3390/jcm11226714
   Web of Science ®Google Scholar
• Tsuchida T. Systemic Lupus Erythematosus. Brain Nerve. 2019;71(4):317–321. doi:10.11477/mf.1416201268
   PubMedGoogle Scholar
• Li S, Gong T, Peng Y. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009 – 2016 US Medicare population. Lupus. 2019;1–12. doi:10.1177/0961203319888691
   Web of Science ®Google Scholar
• Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515–532. doi:10.1038/s41584-021-00668-1
   PubMed Web of Science ®Google Scholar
• Lee WS, Amengual O. B cells targeting therapy in the management of systemic lupus erythematosus. Immunol Med. 2020;43(1):16–35. doi:10.1080/25785826.2019.1698929
   PubMedGoogle Scholar
• Hamijoyo L, Candrianita S, Rahmadi AR, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. Lupus. 2019;28(13):1604–1609. doi:10.1177/0961203319878499
   PubMed Web of Science ®Google Scholar
• Abdullah K, Afrizal A, Diah M, Gani A. The association of platelet-lymphocyte ratio and carotid intima-media thickness in systemic lupus erythematosus patients. Int J Res Publ. 2022;102(1):136–141. doi:10.47119/ijrp1001021620223246
   Google Scholar
• Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16(1):19–30. doi:10.1007/s12519-019-00229-3
   PubMed Web of Science ®Google Scholar
• Ameer MA, Chaudhry H, Mushtaq J, et al. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus. 2022;14(10). doi:10.7759/cureus.30330
   Web of Science ®Google Scholar
• Sutanto H, Yuliasih Y. Disentangling the Pathogenesis of Systemic Lupus Erythematosus: close Ties between Immunological, Genetic and Environmental Factors. Medicine. 2023;59(6):1033. doi:10.3390/medicina59061033
   Google Scholar
• Maidhof W, Hilas O. Lupus: an overview of the disease and management options. Pharm Ther. 2012;37(4):240–249.
   Google Scholar
• Theodorou E, Nezos A, Antypa E, et al. B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun. 2018;92:87–92. doi:10.1016/j.jaut.2018.05.002
   PubMed Web of Science ®Google Scholar
• Robinson GA, Wilkinson MGL, Wincup C. The Role of Immunometabolism in the Pathogenesis of Systemic Lupus Erythematosus. Front Immunol. 2022;12:1–9. doi:10.3389/fimmu.2021.806560
   Web of Science ®Google Scholar
• Santillán-López E, Muñoz-Valle JF, Oregon-Romero E, et al. Analysis of TNFSF13B polymorphisms and BAFF expression in rheumatoid arthritis and primary Sjögren’s syndrome patients. Mol Genet Genomic Med. 2022;10(6):1–16. doi:10.1002/mgg3.1950
   Web of Science ®Google Scholar
• Ortiz-Aljaro P, Montes-Cano MA, García-Lozano JR, et al. Protein and functional isoform levels and genetic variants of the BAFF and April pathway components in systemic lupus erythematosus. Sci Rep. 2022;12(1):1–10. doi:10.1038/s41598-022-15549-0
   PubMed Web of Science ®Google Scholar
• González-serna D, Ortiz-fernández L, Vargas S, et al. Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus. Sci Rep. 2018:1–5. doi:10.1038/s41598-018-26573-4
   PubMed Web of Science ®Google Scholar
• Marín-Rosales M, Cruz A, Salazar-Camarena DC, et al. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med. 2019;19(2):183–190. doi:10.1007/s10238-019-00549-8
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Schneider P, MacKay F. The BAFF/April system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365–373. doi:10.1038/nrrheum.2014.33
   PubMed Web of Science ®Google Scholar
• Croca S, Rahman A. Atherosclerosis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):364–372. doi:10.1016/j.berh.2017.09.012
   PubMed Web of Science ®Google Scholar
• Khairy N, Ezzat Y, Naeem N, Taha R, Wesam R. Atherosclerosis biomarkers in female systemic lupus erythematosus patients with and without cardiovascular diseases. Egypt Rheumatol. 2017;39(1):7–12. doi:10.1016/j.ejr.2016.03.003
   Web of Science ®Google Scholar
• Koulouri V, Koutsilieris M, Mavragani CP. B cells and atherosclerosis in systemic lupus erythematosus. Expert Rev Clin Immunol. 2019;15(4):417–429. doi:10.1080/1744666X.2019.1571411
   PubMed Web of Science ®Google Scholar
• Reiss AB, Jacob B, Ahmed S, Carsons SE, DeLeon J. Understanding accelerated atherosclerosis in systemic lupus erythematosus: toward better treatment and prevention. Inflammation. 2021;44(5):1663–1682. doi:10.1007/s10753-021-01455-6
   PubMed Web of Science ®Google Scholar
• Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol. 2013;62(3):255–262. doi:10.1097/FJC.0b013e31829dd857
   PubMed Web of Science ®Google Scholar
• Wilhelm AJ, Major AS. Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int J Clin Rheumatol. 2014;7(5):527–539. doi:10.2217/ijr.12.46
   Google Scholar
• Sacre K, Escoubet B, Zennaro MC, Chauveheid MP, Gayat E, Papo T. Overweight is a major contributor to atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease. Medicine. 2015;94(48):1–6. doi:10.1097/MD.0000000000002177
   Web of Science ®Google Scholar
• Mak A, Kow NY, Schwarz H, Gong L, Tay SH, Ling LH. Endothelial dysfunction in systemic lupus erythematosus - A case-control study and an updated meta-analysis and meta-regression. Sci Rep. 2017;7(1):1–10. doi:10.1038/s41598-017-07574-1
   PubMedGoogle Scholar
• Lertratanakul A, Sun J, Wu PW, et al. Risk factors for changes in carotid intima media thickness and plaque over 5 years in women with systemic lupus erythematosus. Lupus Sci Med. 2021;8(1):1–10. doi:10.1136/lupus-2021-000548
   Web of Science ®Google Scholar
• Gummadi AC, Guddati AK. Genetic Polymorphisms in Pharmaceuticals and Chemotherapy. World J Oncol. 2021;12(5):149–154. doi:10.14740/wjon1405
   PubMedGoogle Scholar
• Barliana MI, Afifah NN, Amalia R, Hamijoyo L, Abdulah R. Genetic polymorphisms and the clinical response to systemic lupus erythematosus treatment towards personalized medicine. Front Pharmacol. 2022;13:1–14. doi:10.3389/fphar.2022.820927
   Web of Science ®Google Scholar
• Porta S, Danza A, Saavedra MA, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9):1–13. doi:10.3390/jcm9092709
   Web of Science ®Google Scholar
• Bae SC, Gordon C, Urowitz MB, Gladman D, Iban D. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthri Care Res. 2010;62(6):881–887. doi:10.1002/acr.20122
   Web of Science ®Google Scholar
• Mok CC, Tse SM, Chan KL, Ho LY. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus. 2017;2:1–6.
   Google Scholar
• Indonesian Rheumatology Association. Recommendations from the Indonesian Rheumatology Association: Diagnosis and Treatment of Systemic Lupus Erythematosus. Indonesian Rheumatology Association; 2019.
   Google Scholar
• Dahlström Sjöwall C. The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable. Lupus. 2019;28(6):778–782. doi:10.1177/0961203319846388
   PubMed Web of Science ®Google Scholar
• Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019;1(2):e95–e102. doi:10.1016/S2665-9913(19)30037-2
   PubMedGoogle Scholar
• Golder V, Kandane-Rathnayake R, Hoi AYB, et al. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther. 2016;18(1):1–10. doi:10.1186/s13075-016-1163-2
   PubMedGoogle Scholar
• Parodis I, Nikpour M. How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. Ann Rheum Dis. 2021;80(7):5–6. doi:10.1136/annrheumdis-2019-215650
   Web of Science ®Google Scholar
• Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615–1621. doi:10.1136/annrheumdis-2015-207726
   PubMed Web of Science ®Google Scholar
• Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 Phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(5):629–633. doi:10.1136/annrheumdis-2018-214427
   PubMed Web of Science ®Google Scholar
• Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N. Excessive Production of IFN-γ in Patients with Systemic Lupus Erythematosus and Its Contribution to Induction of B Lymphocyte Stimulator/B Cell-Activating Factor/TNF Ligand Superfamily-13B. J Immunol. 2008;181(3):2211–2219. doi:10.4049/jimmunol.181.3.2211
   PubMed Web of Science ®Google Scholar
• Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1–13. doi:10.1016/j.jaut.2018.11.001
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim HA, Suh CH, Jung JY. Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus. Front Med. 2022;9:1–15. doi:10.3389/fmed.2022.906475
   Web of Science ®Google Scholar
• Hoffman RW, Merrill JT, Alarcón-Riquelme MME, et al. Gene expression and pharmacodynamic changes in 1760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab. Arthritis Rheumatol. 2017;69(3):643–654. doi:10.1002/art.39950
   PubMed Web of Science ®Google Scholar
• Ding J, Su S, You T, et al. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. Clinics. 2020;75:1–10. doi:10.6061/clinics/2020/e1801
   Web of Science ®Google Scholar
• Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival. Front Immunol. 2018;9:1–10. doi:10.3389/fimmu.2018.02285
   PubMed Web of Science ®Google Scholar
• González-Serna D, Carmona EG, Ortego-Centeno N, et al. A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PLoS One. 2018;13(12):1–9. doi:10.1371/journal.pone.0209343
   Web of Science ®Google Scholar
• Friebus-Kardash J, Trendelenburg M, Eisenberger U, et al. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrol. 2019;20(1):1–10. doi:10.1186/s12882-019-1623-4
   PubMed Web of Science ®Google Scholar
• Indriani F, Oktarianti R, Wathon S. Genetic Study of Phenylthiocarbamide (PTC) taste sensitivity in population of the osing in kemiren village-banyuwangi. Berk SAINSTEK. 2021;9(1):1. doi:10.19184/bst.v9i1.19844
   Google Scholar
• Herrero-Fernandez B, Gomez-Bris R, Somovilla-Crespo B, Gonzalez-Granado JM. Immunobiology of atherosclerosis: a complex net of interactions. Int J Mol Sci. 2019;20(21). doi:10.3390/ijms20215293
   PubMed Web of Science ®Google Scholar
• Varma MA, Mundkur L, Kakkar VV. Autoimmune Diseases and Atherosclerosis: the Inflammatory Connection. Curr Immunol Rev. 2013;8(4):297–306. doi:10.2174/157339512804806206
   Google Scholar
• Moss JW. Interferon-γ: promising therapeutic target in atherosclerosis. World J Exp Med. 2015;5(3):154. doi:10.5493/wjem.v5.i3.154
   PubMedGoogle Scholar
• Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:1–11. doi:10.3389/fimmu.2019.00119
   PubMed Web of Science ®Google Scholar
• Nezos A, Evangelopoulos ME, Mavragani CP. Genetic contributors and soluble mediators in prediction of autoimmune comorbidity. J Autoimmun. 2019;104:102317. doi:10.1016/j.jaut.2019.102317
   PubMed Web of Science ®Google Scholar
• Liu J, Liao MQ, Cao DF, et al. The association between interleukin-6 gene polymorphisms and risk of systemic lupus erythematosus: a meta-analysis with trial sequential analysis. Immunol Invest. 2021;50(2–3):259–272. doi:10.1080/08820139.2020.1769646
   PubMed Web of Science ®Google Scholar
• Mejía-Vilet JM, Ayoub I. The use of glucocorticoids in lupus nephritis: new pathways for an old drug. Front Med. 2021;8:1–11. doi:10.3389/fmed.2021.622225
   Web of Science ®Google Scholar
• Sestan M, Kifer N, Arsov T, et al. The role of genetic risk factors in pathogenesis of childhood-onset systemic lupus erythematosus. Curr Issues Mol Biol. 2023;45(7):5981–6002. doi:10.3390/cimb45070378
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update in the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14–25. doi:10.1136/annrheumdis-2020-218272
   PubMed Web of Science ®Google Scholar
• Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. Int J Rheum Dis. 2020;23(4):465–471. doi:10.1111/1756-185X.13817
   PubMed Web of Science ®Google Scholar
• Amissah Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2010;1(4):163–175. doi:10.1177/2040622310380100
   PubMedGoogle Scholar
• Kelley C, Vander Molen J, Choi J, et al. Impact of glucocorticoids on cardiovascular system—the yin yang effect. J Pers Med. 2022;12(11). doi:10.3390/jpm12111829
   Web of Science ®Google Scholar
• Babaoglu H, Li J, Goldman D, Magder LS, Petri M. Predictors of predominant lupus low disease activity state (LLDAS-50). Lupus. 2017;176(12):139–148. doi:10.1177/0961203319886028.Predictors
   Google Scholar
• Macleod C, Hadoke PWF, Nixon M. Glucocorticoids: fuelling the fire of atherosclerosis or therapeutic extinguishers? Int J Mol Sci. 2021;22(14). doi:10.3390/ijms22147622
   Web of Science ®Google Scholar
• Moaaz M, Mohannad N. Association of the polymorphisms of TRAF1 (rs10818488) and TNFAIP3 (rs2230926) with rheumatoid arthritis and systemic lupus erythematosus and their relationship to disease activity among Egyptian patients. Cent Eur J Immunol. 2016;41(2):165–175. doi:10.5114/ceji.2016.60991
   PubMed Web of Science ®Google Scholar
• McMahon M, Seto R, Skaggs BJ. Cardiovascular disease in systemic lupus erythematosus. Rheumatol Immunol Res. 2021;2(3):157–172. doi:10.2478/rir-2021-0022
   PubMedGoogle Scholar
• Shimizu H, Takahashi M, Takeda SI, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation. 2004;77(11):1661–1667. doi:10.1097/01.TP.0000127592.13707.B6
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24(5):517–525. doi:10.1016/j.healun.2005.02.002
   PubMed Web of Science ®Google Scholar
• Sazliyana S, Mohd Shahrir MS, Kong CN, Tan HJ, Hamidon BB, Azmi MT. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus. 2011;20(12):1260–1266. doi:10.1177/0961203311411347
   PubMed Web of Science ®Google Scholar
• Sato-Okabayashi Y, Isoda K, Heissig B, et al. Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis. IJC Hear Vasc. 2020;28:1–10. doi:10.1016/j.ijcha.2020.100529
   Web of Science ®Google Scholar
• Kiani AN, Magder LS, Petri M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int. 2012;23(1):1–7. doi:10.1007/s00296-011-2048-y
   Google Scholar
• Wahadat MJ, Van Den Berg L, Timmermans D, et al. LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med. 2021;8(1):1–5. doi:10.1136/lupus-2021-000571
   Web of Science ®Google Scholar
• Waldron D. RNA: differential regulation of APA isoforms. Nat Rev Genet. 2016;17(2):66. doi:10.1038/nrg.2015.33
   PubMedGoogle Scholar
• Piga M, Arnaud L. The main challenges in systemic lupus erythematosus: where do we stand? J Clin Med. 2021;10(2):1–12. doi:10.3390/jcm10020243
   Web of Science ®Google Scholar
• Ji L, Xie W, Fasano S, Zhang Z. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis. Lupus Sci Med. 2022;9(1):1–8. doi:10.1136/lupus-2021-000603
   Web of Science ®Google Scholar
• Hao Y, Oon S, Ji L, et al. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. Clin Rheumatol. 2022;41(2):357–366. doi:10.1007/s10067-021-05940-z
   PubMed Web of Science ®Google Scholar